At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 152 enrolled
Drug / intervention
Tricaprilin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability and Efficacy Study of Tricaprilin (AC-1202) Administered for Ninety Days in Subjects With Probable Alzheimer's Disease of Mild to Moderate Severity
In Brief
A Phase 2 clinical trial evaluating Tricaprilin and Placebo for Alzheimer's Disease. Completed, enrolled 152 participants across 25 sites.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability and effectiveness of tricaprilin administered once a day for ninety days in subjects with mild to moderate, probable Alzheimer's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2004
First PostedSep 2005
Primary CompletionJun 2006
Study CompletionJan 2007
TodayJul 2026
First PostedSep 2, 2005
Enrollment StartNov 4, 2004
Primary CompletionJun 29, 2006
Study CompletionJan 7, 2007
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 20.8 years ago
Interventions
Tricaprilindrug
Powder formulation will be mixed in a liquid (approximately 8 oz).
Placeboother
Powder formulation will be mixed in a liquid (approximately 8 oz).